Feng Ren

Feng Ren, Ruoyu Qin, Teng Ma et al.

Modern GPU clusters are built upon a complex hierarchy of heterogeneous interconnects, ranging from multi-rail RDMA to proprietary fabrics such as Multi-Node NVLink and Ascend UB. Orchestrating these diverse links effectively remains a critical challenge in disaggregated LLM serving. Operating Mooncake TE on thousands of GPUs exposed a critical limitation shared by existing frameworks: imperative, statically bound path selection. This rigidity forces engines to rely on state-blind striping that ignores congestion signals, creating communication silos, wasting multi-rail bandwidth due to head-of-line blocking, and leading to operational fragility where routine faults require manual intervention. We present TENT, a data-movement engine that decouples transfer intent from physical execution. Instead of locking workloads to fixed backends, TENT unifies heterogeneous interconnects into a single dynamic resource pool. Applications simply declare transfer intents, while TENT dynamically decomposes elephant flows into fine-grained slices and "sprays" them across links based on instantaneous link quality. This telemetry-driven orchestration eliminates head-of-line blocking and enables transparent, sub-50 ms self-healing by rerouting slices around failures without application logic. TENT serves as the production data plane for LLM inference and RL pipelines at multiple industrial sites. Our evaluation on H800 HGX clusters shows that TENT outperforms state-of-the-art baselines, including Mooncake TE, NIXL, and UCCL. In LLM inference with SGLang HiCache, TENT achieves up to 1.36x higher throughput and 26% lower P90 TTFT than Mooncake TE. In RL pipelines, TENT accelerates parameter updates in Moonshot Checkpoint Engine by 20-26%.

Xun Sun, Shaoyuan Chen, Pingchuan Ma et al.

Mixture-of-Experts (MoE) serving relies on wide expert parallelism (EP) to aggregate the memory capacity and bandwidth of many GPUs within one inference instance. This efficiency comes with a systems cost: every decoding step depends on token dispatch and combination across all active EP ranks, so even one rank failure can disrupt the entire service. Existing EP stacks handle such failures poorly because they treat membership as a fixed configuration established at initialization. The same rank set determines communicator state, expert placement, and the routing metadata baked into CUDA execution graphs, leaving the system with no way to shrink around a failure while keeping the instance valid. This paper argues that partial-failure tolerance should instead be formulated as a live EP validity problem. We present EEP, a communication and runtime substrate that represents membership as explicit, mutable runtime state. EEP repairs the specific state invalidated by a fault: it restores peer reachability without rebuilding the communication substrate, repairs lost expert coverage through a bandwidth-aware hierarchy, and reintegrates repaired ranks without forcing healthy ranks to recapture their CUDA graphs. We implement EEP in an EP serving stack integrated with SGLang and evaluate it under steady-state serving, failure recovery, and rank reintegration. The results show that explicit mutable membership preserves the steady-state fast path, staying within 4.4% of a fixed-membership DeepEP baseline under static serving, while turning a local rank fault from whole-instance downtime into two bounded interruptions. On a single-rank failure workload, EEP incurs an 11s recovery pause and an 8s reintegration pause, and restores throughput to within 95% of the pre-fault level within 52s, whereas a fixed-membership full-restart baseline remains unavailable until 348s.

Mohammad Ghazi Vakili, Christoph Gorgulla, AkshatKumar Nigam et al.

The discovery of small molecules with therapeutic potential is a long-standing challenge in chemistry and biology. Researchers have increasingly leveraged novel computational techniques to streamline the drug development process to increase hit rates and reduce the costs associated with bringing a drug to market. To this end, we introduce a quantum-classical generative model that seamlessly integrates the computational power of quantum algorithms trained on a 16-qubit IBM quantum computer with the established reliability of classical methods for designing small molecules. Our hybrid generative model was applied to designing new KRAS inhibitors, a crucial target in cancer therapy. We synthesized 15 promising molecules during our investigation and subjected them to experimental testing to assess their ability to engage with the target. Notably, among these candidates, two molecules, ISM061-018-2 and ISM061-22, each featuring unique scaffolds, stood out by demonstrating effective engagement with KRAS. ISM061-018-2 was identified as a broad-spectrum KRAS inhibitor, exhibiting a binding affinity to KRAS-G12D at $1.4 μM$. Concurrently, ISM061-22 exhibited specific mutant selectivity, displaying heightened activity against KRAS G12R and Q61H mutants. To our knowledge, this work shows for the first time the use of a quantum-generative model to yield experimentally confirmed biological hits, showcasing the practical potential of quantum-assisted drug discovery to produce viable therapeutics. Moreover, our findings reveal that the efficacy of distribution learning correlates with the number of qubits utilized, underlining the scalability potential of quantum computing resources. Overall, we anticipate our results to be a stepping stone towards developing more advanced quantum generative models in drug discovery.

Feng Ren, Xiao Ding, Min Zheng et al.

The AlphaFold computer program predicted protein structures for the whole human genome, which has been considered as a remarkable breakthrough both in artificial intelligence (AI) application and structural biology. Despite the varying confidence level, these predicted structures still could significantly contribute to structure-based drug design of novel targets, especially the ones with no or limited structural information. In this work, we successfully applied AlphaFold in our end-to-end AI-powered drug discovery engines constituted of a biocomputational platform PandaOmics and a generative chemistry platform Chemistry42, to identify a first-in-class hit molecule of a novel target without an experimental structure starting from target selection towards hit identification in a cost- and time-efficient manner. PandaOmics provided the targets of interest and Chemistry42 generated the molecules based on the AlphaFold predicted structure, and the selected molecules were synthesized and tested in biological assays. Through this approach, we identified a small molecule hit compound for CDK20 with a Kd value of 8.9 +/- 1.6 uM (n = 4) within 30 days from target selection and after only synthesizing 7 compounds. Based on the available data, the second round of AI-powered compound generation was conducted and through which, a more potent hit molecule, ISM042-2 048, was discovered with a Kd value of 210.0 +/- 42.4 nM (n = 2), within 30 days and after synthesizing 6 compounds from the discovery of the first hit ISM042-2-001. To the best of our knowledge, this is the first reported small molecule targeting CDK20 and more importantly, this work is the first demonstration of AlphaFold application in the hit identification process in early drug discovery.